中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (7): 491-496.doi: 10.19401/j.cnki.1007-3639.2018.07.003

• 专家述评与论著 • 上一篇    下一篇

美国癌症联合委员会甲状腺癌分期系统(第8版)修订对甲状腺乳头状癌分期的影响

张 磊1,董云伟2,胡神保3,杨进宝4,曹 越5,刘跃武5,梁 峰6,石 华7,刘子文5,陈 革5,陈曙光5,商中华8,孙庆贺9,李延龙10,李小毅5   

  1. 1. 中国医学科学院北京协和医学院北京协和医院肝外科,北京100730 ;
    2. 山西省忻州市人民医院普通外科,山西 忻州 034000 ;
    3. 湖北省荆门市第一人民医院普通外科,湖北 荆门 448000 ;
    4. 中国人民解放军白求恩国际和平医院普外二科,河北 石家庄 050082 ;
    5. 中国医学科学院北京协和医院基本外科,北京100730 ;
    6. 河北北方学院附属第一医院普外科,河北 张家口075000 ;
    7. 冀州市医院外科,河北 冀州053200 ;
    8. 山西医科大学第二医院普外科,山西 太原030001 ;
    9. 沧州市人民医院普通外科,河北 沧州 061000 ;
    10. 中国医学科学院基础医学研究所,北京100005
  • 出版日期:2018-07-30 发布日期:2018-08-10
  • 通信作者: 李小毅 E-mail: li.xiaoyi@263.net

The impact of American Cancer Joint Committee Revised Thyroid Cancer Staging System (8th edition)on staging of papillary thyroid carcinoma

ZHANG Lei1, DONG Yunwei2, HU Shenbao3, YANG Jinbao4, CAO Yue5, LIU Yuewu5, LIANG Feng6, SHI Hua7, LIU Ziwen5, CHEN Ge5, CHEN Shuguang5, SHANG Zhonghua8, SUN Qinghe9, LI Yanlong10, LI Xiaoyi5   

  1. 1. Department of Liver Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; 2. Department of General Surgery, Shanxi Xinzhou People’s Hospital, Xinzhou 034000, Shanxi Province, China; 3. Department of General Surgery, Jingmen No.1 People’s Hospital, Jingmen 448000, Hubei Province, China; 4. Second Department of General Surgery, Bethune International Peace Hospital of PLA, Shijiazhuang 050082, Hebei Province, China; 5. Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China; 6. Department of General Surgery, the First Affiliated Hospital of Hebei Northern Medical College, Zhangjiakou 075000, Hebei Province, China; 7. Department of Surgery, Jizhou City Hospital, Jizhou 053200, Hebei Province, China; 8. Department of General Surgery, the Second Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China; 9. Department of General Surgery, Cangzhou People’s Hospital, Cangzhou 061000, Hebei Province, China; 10. Institute of Basic Medical Sciences, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100005, China
  • Published:2018-07-30 Online:2018-08-10
  • Contact: LI Xiaoyi E-mail: li.xiaoyi@263.net

摘要: 背景与目的:2017年美国癌症联合委员会发布了TNM分期系统第8版(TNM-8),该研究旨在比较TNM-8和第7版(TNM-7)分期规则下甲状腺乳头状癌(papillary thyroid carcinoma,PTC)患者分期的变化。方法:该研究共纳入2013—2015年因甲状腺乳头状癌而在中国医学科学院北京协和医学院北京协和医院行初治手术治疗的患者4 265例,手术范围至少包括患侧腺叶切除及患侧淋巴结清扫。根据年龄、性别、肿瘤大小、侵犯范围、淋巴结转移情况及远处转移情况,分别应用TNM-7及TNM-8分期规则进行分期,并对结果进行比较。结果:4 265例患者中,男性1 069例,女性3 196例。根据TNM-7分期,Ⅰ、Ⅱ、Ⅲ、Ⅳa、Ⅳb和Ⅳc期患者数量分别为3 093例(72.50%)、23例(0.54%)、942例(22.09%)、199例(4.67%)、1例(0.02%)和7例(0.16%);而根据TNM-8分期,Ⅰ、Ⅱ、Ⅲ和Ⅳb期患者数量则分别为3 996例(93.60%)、259例(6.00%)、9例(0.20%)和1例(0.02%)。共有1 163例(27.3%)患者分期发生了调整,均为降期。降期原因包括年龄的划分升至55岁(781例,67.1%)、TNM分期规则调整(265例,22.8%)和T分期规则调整(117例,10.1%)。在3 059例微小癌患者中,根据TNM-7分期,Ⅰ~Ⅳ期的患者数量分别为2 323例(75.94%)、3例(0.10%)、649例(21.22%)和84例(2.70%);根据TNM-8分期,Ⅰ~Ⅳ期的患者数量则分别为2 917例(95.30%)、138例(4.50%)、3例(0.10%)和1例(0.03%)。结论:应用TNM-8,与TNM-7相比,Ⅲ~Ⅳ期患者比例大幅减少,对于微小癌患者该特点更加突出,能更好地反映疾病的严重程度。

关键词: 甲状腺乳头状癌, TNM分期系统, 第8版

Abstract: Background and purpose: The TNM staging system was updated to eighth edition (TNM-8) in 2017 by American Joint Committee on Cancer (AJCC). The purpose of this study was to compare staging results of the papillary thyroid carcinoma (PTC) using TNM-8 and seventh edition (TNM-7) staging systems. Methods: A total of 4 265 patients who were diagnosed with PTC and underwent primary surgery at the Peking Union Medical College Hospital from 2013 to 2015 were reviewed. The extent of surgery included lobectomy and ipsilateral lymph node dissection at least. According to age, gender, tumor size, extent of invasion, lymph node metastasis and distant metastasis, TNM-7 and TNM-8 staging systems were used for staging, and the results were compared. Results: A total of 4 265 patients (1 069 males and 3 196 females) were included. According to TNM-7 system, the number of patients with stage Ⅰ, Ⅱ, Ⅲ, Ⅳa, Ⅳb and Ⅳc were 3 093 (72.50%), 23 (0.54%), 942 (22.09 %), 199 (4.67%), 1 (0.02%) and 7 (0.16%), respectively. Using TNM-8 system, the number of patients with stage Ⅰ, Ⅱ, Ⅲ and IVb were 3 996 (93.60%), 259 (6.00%), 9 (0.20%) and 1 (0.02%), respectively. A total of 1 163 patients (27.3%) were down-staged. The reasons for the down-staging included the adjustment of age to 55 years (781 cases, 67.1%), the adjustment of TNM staging rules (265 cases, 22.8%), and the adjustment of T staging rules (117 cases, 10.1%). In 3 059 microcarcinoma patients, the numbers of Ⅰ-Ⅳ patients by TNM-7 were 2 323 (75.94%), 3 (0.10%), 649 (21.22%) and 84 (2.70%), respectively. By TNM-8, the numbers were 2 917 (95.30%), 138 (4.50%), 3 (0.10%) and 1 (0.03%), respectively. Conclusion: With the TNM-8, the proportion of patients with stage Ⅲ-Ⅳ is significantly decreased. This feature is even more prominent in patients with microcarcinoma, and can better indicate the severity of the disease.

Key words: Papillary thyroid carcinoma, TNM staging system, Eighth edition